Drug Trial Radar · NCT00441103
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jul 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Dec 2006
Primary completion
Nov 2008
Study completion Feb 2009
Sponsor
- Lead sponsor
- Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes. Objectives: Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a \[IFN-beta-1a\], RNF), compared to placebo, in subjects with Relapsing Remitting Multiple Sclerosis and active disease by means of Magnetic Resonance Imaging (MRI) at the end of 16 weeks of treatment Secondary: To evaluate the efficacy of RNF by comparing the mean number of combined unique (CU) lesions per scan per subject between the initial 16 weeks of placebo treatment and 24 weeks of RNF treatment in the same subjects, originally randomized to placebo. Primary Endpoints: The primary endpoint is the difference between the number of CU active MRI lesions at Week 16 in the RNF group (Group 1) versus the placebo group (Group 2). Secondary Endpoints: The secondary endpoint is the difference in the mean number of CU active MRI lesions per scan per subject over the following treatment periods: Study Day 1 - Week 16 versus Weeks 17 - 40 for the subjects randomized to Group 2.
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
Rebif® New Formulation (IFN-beta-1a, RNF)Drug
RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
PlaceboDrug
Matching placebo will be administered subcutaneously three times a week for 16 weeks.
Rebif® New Formulation (IFN-beta-1a, RNF)Drug
RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Combined Unique (CU) Active Magnetic Resonance Imaging (MRI) Lesions at Week 16Time frame: 16 Weeks
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Week 40
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.